-
2024-512633-32-00
4
2025-04-07
Crohn's disease
-
2024-512496-12-00
5
2025-04-01
Moderate to Severe Plaque Psoriasis
-
2024-515445-42-00
5
2025-03-24
Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast
-
2023-508307-21-00
5
2025-03-19
Prader-Willi syndrome
-
2023-509070-36-00
5
2025-03-18
Major Depressive Disorder with Insomnia Symptoms
-
2024-514594-21-00
5
2025-03-13
Heterozygous Familial Hypercholesterolemia
-
2024-515034-33-00
9
2025-03-05
Mantle Cell Lymphoma
-
2024-516380-81-00
4
2025-02-28
Treatment of IgAN
-
2024-517262-41-00
5
2025-02-28
Juvenile Psoriatic Arthritis (JPsA)
-
2022-500747-21-00
4
2025-02-27
Geographic Atrophy
-
2022-502352-31-00
5
2025-02-10
Colorectal Cancer (CRC)
-
2024-511652-40-00
5
2025-02-05
METASTATIC CASTRATION RESISTANT PROSTATE CANCER
-
2023-508234-34-00
4
2025-01-27
Crohn's disease
-
2023-510322-32-00
5
2025-01-27
patients with incurable, metastatic/recurrent head and neck squamous c
-
2023-510323-30-00
5
2025-01-24
First-line treatment of recurrent or metastatic PD-L1+ head and neck s
-
2024-514656-32-00
4
2025-01-23
Suspected or confirmed Gram negative infections
-
2024-511775-15-00
4
2025-01-17
Immune system diseases
-
2023-507560-39-00
5
2025-01-07
Acquired Antithrombin Deficiency (Heparin Resistance)
-
2023-510109-16-00
4
2025-01-06
Acute Respiratory Distress Syndrome (ARDS) Due to Pneumonia or other I
-
2023-508813-18-00
4
2024-12-18
Refractory Focal Onset Epilepsy
-
2023-510147-37-00
6
2024-12-18
Chronic Lymphocytic Leukaemia and Moderate to Severe Cardiac Impairmen
-
2023-508180-72-00
4
2024-12-11
Antibody-Mediated Rejection
-
2023-510150-17-00
4
2024-12-11
Active, refractory systemic lupus erythematosus (SLE), and active, re
-
2023-507351-29-00
5
2024-12-03
Alzheimer's Disease Psychosis